| Revenue growth | Reported 2% Y-o-Y growth; adjusted for accounting change 4%. |
|---|---|
| Margins | Current EBITDA 16.7%; guided 18.5-20% for FY27. |
| Demand visibility | Strong traction in obesity and chronic segments. |
| Management confidence | High on U.S. pipeline and chronic therapy momentum. |
Growth
Revenue hit INR 7,119 Cr; One India grew 12% Y-o-Y; US sales at $162M; PAT at INR 789 Cr.
Outlook
EBITDA margin guidance maintained at 18.5%-20% for FY27; targeting $1 billion U.S. exit run-rate by year-end.
Risks
Loss of South African tenders; currency fluctuations; war-related costs impacting margins by 1-2%; inventory write-offs.
Last quarter's promises, checked
Delivered
- Launch generic Ventolin in coming months → Launched in Q1 FY27 (= BEAT)
- India double-digit growth → Delivered 12% Y-o-Y (= BEAT)
- US Albuterol share 19.5% to 20% → Maintained higher-than-proportionate share (= BEAT)
Partly delivered
- 4 US respiratory launches in FY27 → 1 launched, 3 pending (= PARTIAL)
- US $1B exit run-rate target → Current quarterly $162M ($648M annual) (= PARTIAL)
Missed
- EBITDA margin 18.5%-20% → Delivered 16.7% in Q1 (= MISS)
Earnings Call Transcript filed with BSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,399.70
- Market cap
- ₹1,13,076 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 33.5×Sector 50.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Investor Presentation: Key Takeaways
Cipla delivered record Q1 revenue of INR 7,119 Cr, driven by strong growth in India and the US. EBITDA margins stood at 16.7% with PAT at INR 789 Cr.
Cipla Q1 FY27 Results: Net Profit ₹785.5 Cr, Down 39.2% YoY
Cipla Ltd reported revenue from operations of ₹7,119 Cr (+2.3% YoY) and net profit of ₹785.5 Cr (-39.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹785.5 Cr · -39.2% YoY